- Home
- XTKG vs ELTX Comparison
XTKG vs ELTX Comparison
Compare XTKG & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- ELTX
- Stock Information
- Founded
- XTKG 1997
- ELTX 2011
- Country
- XTKG Singapore
- ELTX United States
- Employees
- XTKG N/A
- ELTX N/A
- Industry
- XTKG
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- XTKG
- ELTX Health Care
- Exchange
- XTKG NYSE
- ELTX Nasdaq
- Market Cap
- XTKG 53.6M
- ELTX 54.6M
- IPO Year
- XTKG 2019
- ELTX 2021
- Fundamental
- Price
- XTKG $0.79
- ELTX $5.05
- Analyst Decision
- XTKG
- ELTX Strong Buy
- Analyst Count
- XTKG 0
- ELTX 3
- Target Price
- XTKG N/A
- ELTX $9.50
- AVG Volume (30 Days)
- XTKG 315.8K
- ELTX 27.5K
- Earning Date
- XTKG 12-27-2024
- ELTX 11-13-2024
- Dividend Yield
- XTKG N/A
- ELTX N/A
- EPS Growth
- XTKG N/A
- ELTX N/A
- EPS
- XTKG N/A
- ELTX N/A
- Revenue
- XTKG $15,234,138.00
- ELTX N/A
- Revenue This Year
- XTKG N/A
- ELTX N/A
- Revenue Next Year
- XTKG N/A
- ELTX N/A
- P/E Ratio
- XTKG N/A
- ELTX N/A
- Revenue Growth
- XTKG 51.59
- ELTX N/A
- 52 Week Low
- XTKG $0.08
- ELTX $2.96
- 52 Week High
- XTKG $2.14
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- XTKG 47.92
- ELTX 49.92
- Support Level
- XTKG $0.66
- ELTX $4.72
- Resistance Level
- XTKG $1.34
- ELTX $5.45
- Average True Range (ATR)
- XTKG 0.22
- ELTX 0.37
- MACD
- XTKG -0.09
- ELTX -0.02
- Stochastic Oscillator
- XTKG 9.93
- ELTX 33.61
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.